Literature DB >> 17328080

A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists.

Michael R York1, Taro Nagai, Alyson J Mangini, Raphaël Lemaire, Jean Maguire van Seventer, Robert Lafyatis.   

Abstract

OBJECTIVE: Microarray analyses of peripheral blood leukocytes have shown that patients with systemic lupus erythematosus express increased levels of type I interferon (IFN)-regulated genes. In this study we examined gene expression by peripheral blood mononuclear cells (PBMCs) from patients with systemic sclerosis (SSc) to better understand the dysregulation of the immune system in this disease.
METHODS: PBMC gene expression was analyzed by microarray and confirmed by real-time polymerase chain reaction (PCR). Surface protein expression of Siglec-1 was analyzed by flow cytometry in PBMCs from healthy control subjects and patients with SSc, and in control PBMCs that were cultured in vitro with Toll-like receptor (TLR) agonists.
RESULTS: SSc patients showed increased expression of a cluster of IFN-regulated genes, including Siglec-1 (CD169, sialoadhesin). This result was verified and extended by real-time PCR, showing that a subset of the SSc patients expressed strikingly increased levels of Siglec-1 messenger RNA (mRNA). Flow cytometry of PBMCs from SSc patients and healthy controls showed increased Siglec-1 surface protein expression, which was restricted to CD14+ monocytes. In vitro studies showed that type I IFN and certain TLR agonists, including TLR-7 and TLR-9, induced Siglec-1 mRNA and protein expression. Moreover, TLR induction of surface Siglec-1 was shown to be type I IFN-dependent. Increased numbers of Siglec-1+ cells were observed by immunohistochemistry in the skin of SSc patients compared with healthy controls.
CONCLUSION: Increased expression of Siglec-1 in circulating SSc monocytes and tissue macrophages suggests that type I IFN-mediated activation of monocytes occurs in SSc, possibly through TLR activation of IFN secretion. These observations indicate a potential role for type I IFN-activated monocyte/macrophages in the pathogenesis of SSc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17328080     DOI: 10.1002/art.22382

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  133 in total

1.  Siglec-1 Macrophages and the Contribution of IFN to the Development of Autoimmune Congenital Heart Block.

Authors:  Robert M Clancy; Marc Halushka; Sara E Rasmussen; Tenzin Lhakhang; Miao Chang; Jill P Buyon
Journal:  J Immunol       Date:  2018-12-05       Impact factor: 5.422

Review 2.  Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.

Authors:  Swati Bhattacharyya; Jun Wei; John Varga
Journal:  Nat Rev Rheumatol       Date:  2011-10-25       Impact factor: 20.543

3.  Systemic sclerosis and lupus: points in an interferon-mediated continuum.

Authors:  Shervin Assassi; Maureen D Mayes; Frank C Arnett; Pravitt Gourh; Sandeep K Agarwal; Terry A McNearney; Damien Chaussabel; Nancy Oommen; Michael Fischbach; Kairav R Shah; Julio Charles; Virginia Pascual; John D Reveille; Filemon K Tan
Journal:  Arthritis Rheum       Date:  2010-02

4.  Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis.

Authors:  Peter J Wermuth; Sergio A Jimenez
Journal:  J Immunol       Date:  2012-05-30       Impact factor: 5.422

Review 5.  Macrophage Involvement in Systemic Sclerosis: Do We Need More Evidence?

Authors:  Giuseppina Stifano; Romy Beatriz Christmann
Journal:  Curr Rheumatol Rep       Date:  2016-01       Impact factor: 4.592

Review 6.  Dendritic cells: novel players in fibrosis and scleroderma.

Authors:  Theresa T Lu
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

7.  Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis.

Authors:  Giuseppina Stifano; Thierry Sornasse; Lisa M Rice; Leo Na; Haiyin Chen-Harris; Dinesh Khanna; Angelika Jahreis; Yuqing Zhang; Jeff Siegel; Robert Lafyatis
Journal:  Arthritis Rheumatol       Date:  2018-06       Impact factor: 10.995

Review 8.  Basic and clinical immunology of Siglecs.

Authors:  Stephan von Gunten; Bruce S Bochner
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

Review 9.  Type I interferon in rheumatic diseases.

Authors:  Theresa L Wampler Muskardin; Timothy B Niewold
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

Review 10.  Assessing the human immune system through blood transcriptomics.

Authors:  Damien Chaussabel; Virginia Pascual; Jacques Banchereau
Journal:  BMC Biol       Date:  2010-07-01       Impact factor: 7.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.